Researchers utilized spatial transcriptomics to uncover how HER2-positive gastric cancers evolve resistance to trastuzumab and T-DXd, identifying EMT, ERAD pathways, and metabolic shifts as key survival mechanisms that could inform future sequential treatment strategies.